Biothea

Biothea Pharma is a Boston, Massachusetts-based pharmaceutical company developing needle-free, non-injectable treatments for severe allergic reactions and anaphylaxis. The company's approach aims to provide a convenient, cost-effective alternative to epinephrine auto-injectors, targeting the significant unmet need for accessible anaphylaxis rescue therapy in healthcare and consumer settings. Biothea's platform technology enables drug delivery through non-parenteral routes, reducing barriers to emergency treatment administration. The company was founded in 2021 and is backed by a board of experienced life sciences executives and venture investors.